Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: A prospective, randomized trial of 28 patients

Journal of Clinical Psychiatry

Volumn 70, Issue 3, 2009, Pages 370-377

  Shen, Jianhua ^a,c   Moller, Henry J ^a   Wang, Xuehua ^a   Chung, Sharon A ^a   Shapiro, Gilla K ^a   Li, Xiuying ^a   Shapiro, Colin M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE; ANTIDEPRESSANT AGENT; DRUG DERIVATIVE; MIANSERIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ALERTNESS; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRIVING ABILITY; DRUG EFFECT; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIMULATION; TRAFFIC SAFETY; ATTENTION; CAR DRIVING; COMPARATIVE STUDY; COMPUTER INTERFACE; COMPUTER SIMULATION; DRUG TOXICITY; FOLLOW UP; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOMOTOR PERFORMANCE; STATISTICS; TRAFFIC ACCIDENT; WAKEFULNESS;

ACCIDENTS, TRAFFIC; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ATTENTION; AUTOMOBILE DRIVING; COMPUTER SIMULATION; DEPRESSIVE DISORDER, MAJOR; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOMOTOR PERFORMANCE; USER-COMPUTER INTERFACE; WAKEFULNESS;

EID: 64149122465     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04234     Document Type: Article

References (46)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
2. Ganguli M, Du Y, Dodge HH, et al. Depressive symptoms and cognitive decline in late life: a prospective epidemiological study. Arch Gen Psychiatry 2006;63:153-160
3. Kalska H, Punamaki RL, Makinen-Pelli T, et al. Memory and metamemory functioning among depressed patients. Appl Neuropsychol 1999;6:96-107
4. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999;60(suppl 17):28-31
5. Levitan RD, Shen J, Jindal R, et al. Tryptophan combined with fluoxetine in the treatment of major depression: antidepressant and hypnotic effects. J Psychiatry Neurosci 2000;25:337-346
6. Shen J, Shapiro CM. Polysomnographic sleep effects of fluoxetine and nefazodone on a seasonal affective disorder patient. Sleep Med 2002;3:527-528
7. Rosekind MR. Underestimating the societal costs of impaired alertness: safety, health, and productivity risks. Sleep Med 2005 Jun;6(suppl 1):S21-S25
8. Hobi V, Gastpar M, Gastpar G, et al. Driving ability of depressive patients under antidepressants. J Int Med Res 1982;10:65-81
9. Grabe HJ, Wolf T, Gratz S, et al. The influence of polypharmacological antidepressive treatment on central nervous information processing of depressed patients: implications for fitness to drive. Neuropsychobiology 1998;37:200-204
10. Augsburger M, Donze N, Menetrey A, et al. Concentration of drugs in blood of suspected impaired drivers. Forensic Sci Int 2005;153:11-15
11. Shen J, Chung SA, Kayumov L, et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 2006;51:27-34
12. Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of anti-depressant effect in randomized controlled trials. J Clin Psychiatry 2001;62(suppl 4):17-23
13. Winokur A, Sateis MJ, Hayes JB, et al. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 2000;48:75-78
14. Radhakishun FS, van den Bos J, van der Heijden BC, et al. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 2000;20:531-537
15. Ramaekers JG, Muntjewerff ND, van Veggel LMA, et al. Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Hum Psychopharmacol Clin Exp 1998;13:S87-S97
16. Ridout F, Meadows R, Johnsen S, et al. A placebo-controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 2003 Jun;18(4):261-269
17. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005;66:436-443
18. Willumeit HP, Ott H, Neubert W. Simulated car driving as a useful technique for the determination of residual effects and alcohol interaction after short- and long-acting benzodiazepines. Psychophamacology Suppl 1984;1:182-192
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association; 1994
20. Pinninti NR, Madison H, Musser E, et al. MINI International Neuropsychiatric Schedule: clinical utility and patient acceptance. Eur Psychiatry 2003;18:361-364
21. Gire DH, Schoppa NE. Long-term enhancement of synchronized oscillations by adrenergic receptor activation in the olfactory bulb. J Neurophysiol 2008 Apr;99(4):2021-2025
22. Arnedt JT, Wilde GJ, Munt PW, et al. Simulated driving performance following prolonged wakefulness and alcohol consumption: separate and combined contributions to impairment. J Sleep Res 2000;9:233-241
23. Moller HJ, Kayumov L, Bulmash EL, et al. Simulator performance, microsleep episodes, and subjective sleepiness: normative data using convergent methodologies to assess driver drowsiness. J Psychosom Res 2006;61:335-342
24. Mitler MM, Gujavarty KS, Browman CP. Maintenance of Wakefulness Test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. Electroencephalogr Clin Neurophysiol 1982 Jun;53(6):658-661
25. Doghramji K, Mitler MM, Sangal RB, et al. A normative study of the Maintenance of Wakefulness Test (MWT). Electroencephalogr Clin Neurophysiol 1997 Nov;103(5):554-562
26. Tiihonen M, Partinen M. Polysomnography and Maintenance of Wakefulness Test as predictors of CPAP effectiveness in obstructive sleep apnea. Electroencephalogr Clin Neurophysiol 1998 Dec;107(6):383-386
27. Beck AT, Steer RA, Brown GK. BDI-II, Beck Depression Inventory Manual. 2nd ed. San Antonio, Tex: Psychological Corporation; 1996
28. Verster JC, de Weert AM, Bijtjes SI, et al. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. Psychopharmacology 2003;169:84-90
29. Theunissen EL, Vermeeren A, van Oers AC, et al. A dose-ranging study of the effects of mequitazine on actual driving, memory, and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo. Clin Exp Allergy 2004;34:250-258
30. Vuurman EF, Rikken GH, Muntjewerff ND, et al. Effects of desloradine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004;60:307-313
31. Sagberg F. Road accidents caused by drivers falling asleep. Accid Anal Prev 1999;31:639-649
32. Brunnauer A, Laux G, Geiger E, et al. Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry 2006;67:1776-1781
33. Deery HA, Fildes BN. Young novice driver subtypes: relationship to high-risk behavior, traffic accident record, and simulator driving performance. Hum Factors 1999;41:628-643
34. Sims RV, McGwin G Jr, Allman RM, et al. Exploratory study of incident vehicle crashes among older drivers. J Gerontol A Biol Sci Med Sci 2000;55:M22-M27
35. Wang CC, Carr DB. Older driver safety: a report from the older drivers project. J Am Geriatr Soc 2004;52:143-149
36. Ragland DR, Satariano WA, MacLeod KE. Driving cessation and increased depressive symptoms. J Gerontol A Biol Sci Med Sci 2005 Mar;60(3):399-403
37. Yegneswaran B, Shapiro C. Do sleep deprivation and alcohol have the same effects on psychomotor performance? J Psychosom Res 2007;63:569-572
38. Bulmash EL, Moller HJ, Kayumov L, et al. Psychomotor disturbance in depression: assessment using a driving simulator paradigm. J Affect Disord 2006;93:213-218
39. Marttila M, Jääskeläinen J, Järvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995 Dec;5(4):441-446
40. Montgomery SA, Reimitz, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998;13:63-73
41. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 2001;62:358-361
42. Sarchiapone M, Amore M, De Risio S, et al. Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol 2003;18:35-38
43. Shapiro CM, Bortz R, Mitchell D, et al. Slow-wave sleep: a recovery process after exercise. Science 1981;214:1253-1254
44. Moller HJ, Devins GM, Shen J, et al. Sleepiness is not the inverse of alertness: evidence from four sleep disorder patient groups. Exp Brain Res 2006;173:258-266
45. Thorpy MJ, for the Standards of Practice Committee of the American Sleep Disorders Association. The clinical use of the multiple sleep latency test. Sleep 1992;15:268-276
46. Edwards JG. Depression, antidepressants, and accidents. BMJ 1995;311:887-888